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Motor neuron degeneration in amyotrophic lateral sclerosis (ALS) has a familial cause in 10% of patients.
Despite signiﬁcant advances in the genetics of the disease, many families remain unexplained. We performed
whole-genome sequencing in ﬁve family members from a pedigree with autosomal-dominant classical ALS. A
family-based elimination approach was used to identify novel coding variants segregating with the disease.
This list of variants was effectively shortened by genotyping these variants in 2 additional unaffected family
members and 1500 unrelated population-speciﬁc controls. A novel rare coding variant in SPAG8 on chromo-
some 9p13.3 segregated with the disease and was not observed in controls. Mutations in SPAG8 were not
encountered in 34 other unexplained ALS pedigrees, including 1 with linkage to chromosome 9p13.2–23.3.
The shared haplotype containing the SPAG8 variant in this small pedigree was 22.7 Mb and overlapped
with the core 9p21 linkage locus for ALS and frontotemporal dementia. Based on differences in coverage
depth of known variable tandem repeat regions between affected and non-affected family members, the
shared haplotype was found to contain an expanded hexanucleotide (GGGGCC)n repeat in C9orf72 in the
affected members. Our results demonstrate that rare coding variants identiﬁed by whole-genome sequencing
can tag a shared haplotype containing a non-coding pathogenic mutation and that changes in coverage
depth can be used to reveal tandem repeat expansions. It also conﬁrms (GGGGCC)n repeat expansions in
C9orf72 as a cause of familial ALS.
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Amyotrophiclateralsclerosis(ALS)isaneurodegenerativedis-
order clinically characterized by muscular weakness due to de-
generation of upper and lower motor neurons. Median survival
islimitedbyrespiratoryfailureto3yearsafterdiseaseonset(1).
Extra-motor involvement such as frontal executive deﬁcits or
behavioralproblemsisseeninupto50%ofpatients,buttheclin-
ical criteria for frontotemporal dementia (FTD) are met in only
 5% of patients (2). Adequate treatments are lacking. Familial
and sporadic cases are clinically indistinguishable. In most
instances,accumulationsoftheproteinTDP-43areencountered
atpost-mortemexaminationofthebrainandspinalcord(3).Al-
though only 10% of ALS is familial, the discovery of disease
genes accelerated research into the pathogenic mechanism of
motor neuron degeneration (4). Three genes are relatively fre-
quently encountered in familial ALS. Mutations in SOD1 are
responsible for  20% of familial ALS (5) and mutations in
TARDPB and FUS are each encountered in3–5% (6–9).Muta-
tionsinANG,VAPB,OPTNandVCParelessoftencausingALS
(10–13). Roughly 70% of ALS families remain unexplained
after routine genetic testing. Using linkage analysis in larger
ALS kindreds, loci at chromosome 18q (14) and 20p (15) have
been identiﬁed. In addition, several families with ALS and
FTD have been linked to chromosome 9q (16) and 9p
(17–26). Next-generation sequencing techniques such as
exome-sequencingorwhole-genomesequencingwillaccelerate
the discovery of disease genes.
In this study, we used whole-genome sequencing in a small
kindred of familial ALS in which mutations in SOD1, TARDBP,
FUS, ANG, ATXN2 and GRN were previously excluded (27–
29). We sought for genetic variants that segregated with the
disease in this family and were absent in controls.
RESULTS
Description of the pedigree
A small two-generation pedigree with classical ALS was studied
(Fig. 1). The index patient (III:2) developed dysarthria and dys-
phagia at the age of 40. A progressive bulbar and facial weak-
ness was noted, followed by weakness of the right hand 4
months later. No changes in cognition or personality were appar-
ent, but a pseudobulbar affect with easy laughing was present.
On clinical examination, a combination of upper and lower
m o t o rn e u r o ns i g n sw e r ef o u n di nt h eb u l b a rr e g i o na n di nt h e
limbs. Signs of lower motor neuron degeneration were present
in three body regions on electrodiagnostic testing. The muscle
weakness was steadily progressive and the patient died 22
months after disease onset. Around that time, ALS was diag-
nosed in one of the parents at the age of 72 (II:3). Subject II:3
suffered from progressive bulbar weakness with dysphagia and
dysarthria. After 1 year, progressive muscle weakness and
atrophy in the limbs with upper motor neuron signs were
noted. Lower motor neuron signs were present in three body
regions on electrodiagnostic testing. Death occurred at the age
of 74. Three years later, at the age of 47, subject III:1 presented
with difﬁculty walking caused by muscle weakness and atrophy
in the right leg. At presentation, signs of lower and upper motor
neuron loss in three body regions conﬁrmed the diagnosis.
Electrodiagnostic testing conﬁrmed lower motor neuron involve-
ment in three body regions. The disease progressed to the upper
limbs and survival was limited to 16 months after disease onset.
There was no history of ALS in generation I. I:1 and I:2 died at
the age of 83 and 90, respectively. I:2 developed dementia pre-
senting with memory complaints at the age of 76 years, but no
motor problems were observed. Three siblings of generation two
developed dementia. In 2 of them (II:7 and II:8), this was around
the age of 60 years. Detailed clinical information and DNA was
only available from subjects II:1–4 and subjects III:1–3.
Whole-genome sequencing
We performed whole-genome sequencing on the parents (II:2
not affected and II:3 affected) and three siblings (III:1 and
III:2 affected, III:3 not affected) from this small kindred with
classical rapidly progressive ALS. The inheritance pattern
appearedtobeautosomaldominant.Sequencingwasperformed
at Complete Genomics (Mountain View, CA, USA), read
mapping and variant detection was performed using the CGA
tools
w. Mapped bases after reference assembly and de novo as-
sembly ranged from 188.4 to 338.2 Gb. The fraction of the
genome sequenced in the ﬁve subjects was 89.8% on average
(Supplementary Material, Table S1). The exome coverage was
96.6% on average and was consistently higher than the
genome coverage for all ﬁve subjects. The average haploid
coverage ranged from 44,1x to 74,2x (Supplementary Material,
TableS1).Atleast84.8%ofthegenomeand93.5%oftheexome
wassequencedwithgoodcoverageinallﬁvesubjects.Thetotal
single nucleotide variant (SNV) and small insertions/deletions
(indels) count ranged from 3 045 998 to 3 280 751 and from
332 116 to 402 583, respectively, in the different subjects (Sup-
plementary Material, Table S2).
First, the coding part of the genome was analyzed. The ana-
lysis ﬂow is shown in Supplementary Material, Figure S1. In
the coding region of each genome, 7947– 8666 missense
variants, 24–56 nonsense variants and 302–496 frameshift
variants were identiﬁed (Supplementary Material, Table S2).
Using a family-based elimination approach, 414 missense
mutations, 9 nonsense mutations and 8 frameshift
mutations were retained that segregated with the disease in
this family. After removing the variants also present in the
most recent release of the 1000 Genomes Project or in
dbSNP or in 9 previously sequenced genomes, 39 missense,
1 nonsense and 2 frameshift novel variants were selected as
putative candidate causative mutations (Table 1).
Validation of novel coding variants segregating
with disease
Next, a Sequenom MassAssay was performed for all candidate
mutations. To check the quality of the results obtained from
the whole-genome sequencing, the assay was run on the ﬁve
original DNA samples. This assay failed in validating four
variants due to the primer design. These variants were
checked by Sanger sequencing or Taqman assay. All variants
identiﬁed in the original whole-genome sequencing study were
conﬁrmed (Table 1).
In order to limit the list of candidate mutations, controls
were analyzed. For this purpose, we used three groups of
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breast cancer controls with self-declared Flemish ethnicity
for 3 generations, and 2 additional non-affected family
members, being subject II:1 and II:4). We hypothesized that
the novel variants (segregating with disease and not previously
reported) that are also encountered in population controls or in
two elderly healthy family members are unlikely to be the
causative mutation. More likely, such variants represent very
rare or population-speciﬁc variants. Using this strategy, all
but two variants could be excluded. Both sets of controls pro-
vided complementary information, 27 variants could be
excluded by genotyping the population controls and 28 by
genotyping two additional unaffected family members
(Table 1). The A956V variant in RNF123 (ring ﬁnger
protein 123) and the I121V variation in SPAG8 (sperm-asso-
ciated antigen 8) were not encountered in any of the controls.
Of interest, SPAG8 is located on chromosome 9p13.3, just
outside the narrow locus shared by all ALS-FTD families
linked to 9p21 (17–26), but inside the larger region linked
to ALS-FTD in several families. We therefore further
studied the SPAG8 gene in ALS.
We sequenced the gene in a cohort of unexplained familial
ALS patients seen at the neuromuscular reference center in
Leuven, in whom mutations in SOD1, TARDBP, FUS, ANG,
ATXN2 and GRN were previously excluded (27–29). The 8
exons and intron–exon boundaries of SPAG8 were sequenced
in 43 ALS patients belonging to 33 unrelated pedigrees. Three
additional missense changes (D37A, S110G and R349S) were
found in two different pedigrees, but none of them appeared to
be pathogenic. The D37A variant was found in ALS patients
belonging to a pedigree with slowly progressive ALS, and
the S110G and the R349S variant were observed in a family
with dementia and ALS. The R349S variant was also observed
in 5/1073 controls. The other two variants were absent in con-
trols, but did not segregate with disease within the respective
pedigrees. In addition, no mutations in SPAG8 were found in
an ALS patient from a family with proven linkage to the
9p13.2–21.3 locus (19). Therefore, mutations in SPAG8 are
unlikely to be pathogenic.
Fine-mapping of the shared haplotype around
the SPAG8 gene
Since SPAG8 is located near a locus shared by all ALS-FTD
families with linkage to 9p21, we hypothesized that this
variant was tagging a causal non-coding mutation in this
family. We determined the shared haplotype around the
I121V variant by analyzing the known SNPs on chromosome
9p. The shared haplotype containing the variant was 22.7 Mb
in size (14 041 725–36 734 729) and overlapped with the core
9p21 locus shared by all ALS-FTD families (Fig. 2). Within
the overlapping region of the segregating haplotype and the
core 9p linkage region, which consisted of 3.6 Mb (27 228
617–30 809 382), we analyzed all the novel non-coding var-
iants. Nineteen novel variants segregating with disease were
identiﬁed, of which none was located in conserved regions.
It is therefore unlikely that any of these variants is causing
the disease phenotype. We then assessed structural variants
predicted by the CGA toolsw. None of the structural variants
identiﬁed was segregating with disease. Finally, since simple
tandem repeats can also be involved in causing neurodegen-
erative diseases, we assessed whether variable tandem repeat
expansions were present in affected family members. Since
tandem repeats are often missed by paired-end short-read se-
quencing technologies due to mapping errors, leading to
changes in coverage depth in and around tandem repeats
(30), we assessed coverage depth within the core 9p linkage
region. Theoretically, two different types of mapping errors
can occur when assessing tandem repeat extensions: (i) if
both ends of the paired-end read can effectively be mapped,
the coverage depth in and around the repeat will be increased,
or (ii) if one end of the paired-end read fails to map in the
tandem repeat, there will be low coverage within the repeat
region but increased coverage around the repeat site due to
correct mapping of the other paired-end outside of the repeat
region. We therefore investigated both scenarios in all intra-
genic repeat regions within the core 9p linkage region. For
the ﬁrst scenario, seven tandem repeats with increased cover-
age at the repeat site segregating with disease in our pedigree
Figure 1. Pedigree of family with autosomal-dominant inheritance of ALS. The index patient is shown by the arrow. Age at disease onset and age at death are
shown. Several other family members suffered from dementia, but no detailed clinical information or DNA was available from these family members. N.A.
denotes not applicable.
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second scenario, only one tandem repeat with increased cover-
age depth around the repeat site was found. In particular, a
peak of increased coverage depth in the 300 bps following
the repeat was observed in affected family members (II:3,
III:1 and III:2) but not in non-affected members (II:2 and
III:3) (Fig. 3A). The repeat identiﬁed turned out to be the
very recently described hexanucleotide (GGGGCC)n repeat
in intron 1 of C9orf72 (31–33) as a novel cause of familial
ALS and FTD. The repeat expansion in C9orf72 could not
be observed in the aligned sequences. However, when ampli-
fying the repeat region using polymerase chain reaction (PCR)
affected family members were homozygous for a short repeat
(repeat size of 5), whereas non-affected family members were
Figure 2. Shared haplotype containing I121V variant in SPAG8 map of chromosome 9, showing the location of the core 9p21 locus containing the MOBKL2B,
IFNK and C9orf72 genes and the shared haplotype containing the I121V variant in SPAG8.
Table 1. Novel coding variants segregating with ALS in pedigree FALS3
Gene Gene name Chrom Variant Conﬁrmed Present in 1500 population
controls
Present in 2 family
controls
NUP210L nucleoporin 210kDa-like 1 p.V1196I Yes Yes No
PMF1 Polyamine-modulated factor 1 1 p.R149W Yes Yes No
KIF1B Kinesin family member 1B 1 p.R18Q Yes No Yes
KIF1B Kinesin family member 1B 1 p.E1006G Yes Yes Yes
RNF115 Ring ﬁnger protein 115 1 p.E239D Yes Yes No
MAP3K6 Mitogen-activated protein kinase 6 1 p.R196W Yes No Yes
C1orf59 Chromosome 1 open reading frame 59 1 p.V12I Yes Yes Yes
SCMH1 Sex comb on midleg homolog 1 1 p.P266S Yes Yes Yes
TDRD10 Tudor domain containing 10 1 p.R250C Yes Yes No
AGXT Alanine-glyoxylate aminotransferase 2 p.A280E Yes No Yes
MYO7B Myosin VIIB 2 p.T1124K Yes Yes Yes
CCDC148 Coiled-coil domain containing 148 2 p.Y307F Yes Yes Yes
ATG4B ATG4 autophagy related 4 homolog B 2 p.R90Q Yes Yes Yes
RNF123 Ring ﬁnger protein 123 3 p.A956V Yes No No
DPPA2 Developmental pluripotency associated 2 3 p.A157S Yes Yes Yes
SH3TC1 SH3 domain and tetratricopeptide repeats 1 4 p.L1088M Yes Yes Yes
BRD2 Bromodomain containing 2 6 p.G565D Yes No Yes
TULP1 Tubby like protein 1 6 p.A496T Yes No Yes
CUTA CutA divalent cation tolerance homolog 6 p.C22X Yes – Yes
PSORS1C2 Psoriasis susceptibility 1 candidate 2 6 280delC Yes – Yes
CCDC132 Coiled-coil domain containing 132 7 p.V770I Yes No Yes
SPAG8 Sperm-associated antigen 8 9 p.I121V Yes No No
IFNA7 Interferon, alpha 7 9 p.V129L Yes Yes No
NDOR1 NADPH dependent diﬂavin oxidoreductase 1 9 p.R30G Yes – Yes
GPR133 G protein-coupled receptor 133 12 p.S265Y Yes Yes Yes
MTMR15 Myotubularin related protein 15 15 p.E240K Yes Yes Yes
ICT1 Immature colon carcinoma transcript 1 17 p.E171D Yes No Yes
DNAH17 Dynein, axonemal, heavy chain 17 17 p.Q4387E Yes No Yes
IFT20 Intraﬂagellar transport 20 homolog 17 p.R105Q Yes Yes Yes
DDX52 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 17 p.D5G Yes Yes Yes
EVI2A Ecotropic viral integration site 2A 17 p.G187S Yes Yes Yes
LRRC37B Leucine rich repeat containing 37B 17 p.E510Q Yes – Yes
KRTAP4–8 Keratin associated protein 4–8 17 p.C30X Yes Yes No
ZNF229 Zinc ﬁnger protein 229 19 p.G513R Yes Yes No
CCDC8 Coiled-coil domain containing 8 19 p.N318K Yes Yes No
ZNF534 Zinc ﬁnger protein 534 19 1510delC Yes Yes Yes
PLIN4 Perilipin 4 19 p.V917I Yes Yes No
SLCO4A1 Solute carrier organic anion transporter family,
member 4A1
20 p.V263I Yes Yes No
ARFGAP1 ADP-ribosylation factor GTPase activating protein 1 20 p.K278E Yes Yes No
COL9A3 Collagen, type IX, alpha 3 20 p.P476R Yes Yes No
TSPYL2 Testis-speciﬁc Y-encoded-like protein 2 X p.R353C Yes Yes Yes
FAM47B Family with sequence similarity 47, member B X p.G14V Yes Yes Yes
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and 5). An unampliﬁable repeat expansion can explain this ob-
servation. Using repeat-primed PCR, the expanded hexanu-
cleotide repeat was revealed and was shown to segregate
with disease (Fig. 3B). Although this technique does not
allow accurate measurements of the repeat size, it was esti-
mated to be  80 in this kindred, which is within the range
described in ALS-FTD patients (range 30 to .100, up to 23
in controls) (31,32).
DISCUSSION
Next-generationsequencingtechnologiesareexpectedtoaccel-
erate the discovery of novel disease genes (34). In patients with
familial ALS or ALS-FTD,  50% of pedigrees remain
unexplained. Very few studies using next-generation sequen-
cing have been performed in neurodegenerative disorders.
Exome sequencing has revealed mutations in VCP in familial
ALS (13), mutations in VPS35 in Parkinson’s disease (35,36),
mutations in DNMT1 in a rare form of dementia with hearing
loss and neuropathy (37) and mutations in DNAJC5 in
adult-onset neuronal ceroid lipofuscinosis (38). No whole-
genome studies in neurodegenerative disorders have been
reported.
Because of the challenge of ﬁltering and interpreting the
large number of identiﬁed variants, the few whole-genome se-
quencing studies performed have focused on missense muta-
tions, nonsense mutations or small frameshift variants
(insertions or deletions), similar to exome sequencing studies
(39,40). Due to the mapping of short reads, other genetic var-
iants, such as structural variants of 50–500 bp or repeat
Figure 3. Expanded (GGGGCC)n repeat in C9orf72 in affected family members. (A) GC-corrected coverage depth reveals region with increased coverage depth
in affected family members only in region following (GGGGCC)n repeat in C9orf72.( B) PCR products of repeat-primed PCR demonstrate repeat expansion in
affected family members by the presence of a tail of stutter ampliﬁcation. An example of a non-affected and affected family member is shown.
2416 Human Molecular Genetics, 2012, Vol. 21, No. 11expansions, are difﬁcult to extract from the aligned sequences.
In our small kindred of autosomal-dominant ALS, whole-
genome sequencing data of just ﬁve individuals (three affected
and two unaffected) were used to ﬁnd coding variants that seg-
regated with disease. The list of candidates was dramatically
reduced by the use of family controls and population-speciﬁc
controls. Although we could not demonstrate that the most
promising rare variant represents a pathogenic mutation, the
availability of whole-genome sequencing data allowed us to
delineate a shared haplotype of 22.7 Mb tagged by this rare
coding variant. This haplotype completely overlapped with
the core 9p linkage region and was shown to contain the
very recently described hexanucleotide (GGGGCC)n repeat
expansion in intron 1 of C9orf72 (31–33). This repeat expan-
sion was not apparent from the aligned sequences, but was
identiﬁed when assessing changes in coverage depth of
known variable tandem repeat regions segregating with
disease. The differences in coverage depth between affected
and non-affected family members are possibly due half-
mapped reads. In contrast to the studies that only very recently
identiﬁed an expanded (GGGGCC)n repeat in C9orf72 using
established linkage regions in large families with ALS-FTD,
our whole-genome sequencing was able to pinpoint the same
region using only a small kindred.
C9orf72 encodes an uncharacterized nuclear protein. How
(GGGGCC)n in C9orf72 cause disease is unknown. The
repeat expansion leads to loss of an alternatively spliced tran-
script, possibly to reduced protein expression and to the for-
mation of nuclear RNA foci (31,32). Further studies are
required to elucidate the disease mechanism of this novel
cause of ALS-FTD with TDP-43 pathology.
Our study illustrates caveats in the interpretation of rare var-
iants identiﬁed by current strategies for whole-genome se-
quencing and how rare variants can be useful in tagging a
nearby non-coding true disease-causing mutation and how
changes in coverage depth can reveal repeat expansions. In
addition, the pathogenic nature of (GGGGCC)n repeat expan-
sion in C9orf72 is further supported by our results.
MATERIALS AND METHODS
Subjects
Between 1994 and 2010, DNA samples from patients with fa-
milial ALS and controls seen at the neuromuscular clinic in
Leuven were collected (28). Patients met the revised El Escor-
ial (41) and Awaji criteria (42) of probable ALS. Blood
samples were obtained after informed consent, and this
study was approved by the local ethical committee of the
KU Leuven. After excluding mutations in SOD1, TARDBP,
FUS, ANG, ATXN2 and GRN (27–29), the cause of ALS
remained unexplained in 46 patients belonging to 34 families.
Three affected family members from pedigree FALS3 were
used for whole-genome sequencing. Index patients from the
other unexplained families and from an ALS pedigree with
proven linkage to 9p (19) were used for validating the
results obtained. Population-speciﬁc controls consisted of
900 healthy controls and 600 breast cancer controls.
Whole-genome sequencing
Sample DNA was extracted from whole blood using standard
methods and sequenced at Complete Genomics (Mountain
View, CA, USA) using unchained combinatorial probe
anchor ligation chemistry on self-assembling DNA nanoballs
(DNBs) (43). Raw reads were aligned to the reference
genome (National Center for Biotechnology Information
(NCBI) build 36). Mapped reads were assembled using their
CGA Tool. Variants were called and scored using a local de
novo assembly approach. Sequencing alignment and variant
calling were also performed at Complete Genomics.
Bio-informatic analysis
Variants annotation. All variants from each genome were
annotated independently using Annovar Tool. Coding variants
were selected for further investigation. Coding variants
include missense variants, nonsense variants and frameshift
variants (insertions or deletions).
Family-based elimination approach. The analysis was per-
formed under the assumption that the causative mutation
should be shared by the three affected subjects (II:3, III:1
and III:2) but not present in the two unaffected subjects (II:2
and III:3). This approach was applied to all the coding
variants.
Novel variants selection. To eliminate common germline poly-
morphisms from consideration, variants reported in dbSNP130
or in 1000 genome project 2010 July release were removed.
Variants also identiﬁed in nine in-house Complete Genomics
whole-genome sequenced germline DNA samples from gyne-
cological cancer patients of Flemish origin were considered
population-speciﬁc variants. They were removed as well
from consideration. Only the variants not previously identiﬁed
were considered putative candidate causative mutations.
Detection of the shared haplotype around the I121V variant
in SPAG8. To determine this haplotype, we analyzed SNPs
on chromosome 9. We ﬁrst ﬁltered out SNPs which were iden-
tical in both parents or for which neither of the parents were
heterozygous. Using this list of unique heterozygous SNPs
in the parents, the parental origin for each of these SNPs in
the siblings can be determined. An analysis of consecutive
SNPs in both parents and the three siblings was used to
make an estimation of the haplotype blocks.
Detection of short tandem repeats in shared haplotype. Short
tandem repeats are regions in the genome of minimum six
consecutive bases built up by at least two identical blocks of
2–6 bp. To locate all short tandem repeats in the haplotype
block, we used a tool called ‘grepseq’ (http://code.google.
com/p/grepseq/). This tool scans fasta-ﬁles in search for posi-
tions in the genome that match a given pattern (e.g. ‘short
tandem repeat’). The coverage depth was analyzed in and
around short tandem repeats of at least two consecutive
repeats of 4–6 bp. The coverage depth is a number provided
by Complete Genomics that indicates the amount of times a
given base has been sequenced by different reads. After
Human Molecular Genetics, 2012, Vol. 21, No. 11 2417correcting the coverage depth for the GC bias using a script
from Complete Genomics (UCSC GC-track), we searched
for short tandem repeats with unexpected coverage depth.
Genotyping
Variants identiﬁed by whole-genome sequencing were con-
ﬁrmed using a Sequenome MassAssay system (Sequenom,
San Diego, CA, USA).
Variants that failed genotyping using Sequenom assays
were typed in family and unrelated controls using bidirection
dideoxy sequencing of ampliﬁed products or Taqman genotyp-
ing assays-by-design run on a 7300 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) accord-
ing to the manufacturer’s instructions.
The hexanucleotide repeat region in intron 1 of C9orf72 was
typed by PCR and repeat-primed PCR as previously described
(31,32). The length of fragments generated by repeat-primed
PCR was determined after running on an ABI3130xl seq-
uencer, using GeneMapper software version 4.0 (Applied
Biosystems).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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